Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
General9 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General11 hours agoAlbanese beats drum on economy as trade clouds gather
-
Business8 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
Noosa News11 hours agoSurgeon partner of former premier to testify over his patient’s death